BNFC Naproxen Dose for CNO in a 46 kg Patient
For a 46 kg patient with Chronic Nonbacterial Osteomyelitis (CNO), administer naproxen 500 mg orally twice daily, which falls within the recommended pediatric dosing of approximately 10 mg/kg/day in 2 divided doses (5 mg/kg twice daily). 1
Dosing Rationale
- The FDA-approved pediatric dose for naproxen is approximately 10 mg/kg given in 2 divided doses (i.e., 5 mg/kg given twice a day), which for a 46 kg patient equals 230 mg twice daily 1
- However, since naproxen tablets are not well suited to precise weight-based dosing in this weight range, and given that this patient weighs >40 kg, adult dosing of 250-500 mg twice daily is appropriate 1
- For CNO, which requires sustained anti-inflammatory activity, the recommended dose is 500 mg twice daily to achieve adequate therapeutic effect 1
Formulation Considerations
- Naproxen tablets should be used rather than naproxen suspension for a patient of this weight 1
- The standard adult formulation of 250 mg, 375 mg, or 500 mg tablets twice daily is appropriate 1
- Peak plasma levels are attained in 2 to 4 hours after oral administration, with steady-state levels reached in 4 to 5 days 1
Important Clinical Considerations
- NSAIDs like naproxen are contraindicated or should be used with extreme caution in patients with renal impairment 1, 2
- If "CNO" refers to a condition involving renal compromise (though Chronic Nonbacterial Osteomyelitis is the standard interpretation), naproxen-containing products are not recommended for use in patients with moderate to severe renal impairment (creatinine clearance <30 mL/min) 1
- The morning and evening doses do not have to be equal in size, and administration more frequently than twice daily is not necessary 1
Monitoring and Adjustment
- During long-term administration, the dose may be adjusted up or down depending on clinical response 1
- A lower daily dose may suffice for long-term administration once inflammation is controlled 1
- In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/day for limited periods of up to 6 months when a higher level of anti-inflammatory activity is required 1
- The elimination half-life of naproxen ranges from 12 to 17 hours, allowing for convenient twice-daily dosing 1, 3
Safety Profile
- Naproxen demonstrates linear pharmacokinetics up to 500 mg doses, with predictable plasma concentrations 4, 5
- The drug is well tolerated with an established adverse effect profile over many years of clinical use 3
- Gastrointestinal adverse effects are the most common, and the drug should be taken with food if GI upset occurs 3